Efficacy and Safety of the 64Cu(II)Cl2 PET/CT for Urological Malignancies

Abstract

Purpose of the Report The aim of this study was to evaluate safety and efficacy of copper-64(II)dichloride (64Cu(II)Cl2) as a new PET tracer for urological malignancies (UMs). Methods Patients with UM were enrolled in a prospective study. All patients were staged with preoperative CT and 64Cu(II)Cl2 PET/CT. Patient characteristics, anatomical and functional imaging, and final histopathology were recorded. Surgical specimens for histopathological examination were collected. To determine time-activity curves for 64Cu(II)Cl2 uptake in UM and normal tissues, SUVs were calculated. The safety of 64Cu(II)Cl2 was assessed. Results Twenty-three patients were included. An administered activity of 174.7 MBq (4.72 mCi) for 64Cu(II)Cl2 was equal to 9.80 mSv of the effective dose. The median SUVmax values were 5.7, 0.9, 1.8, and 9.8 for the prostate, bladder, penis, and kidney, respectively. Median SUVmax values were higher in organs with a malignancy in comparison with healthy tissue (prostate [11.5 vs 5.3, P < 0.001], bladder [6.2 vs 0.9, P = 0.007], and penis [3.9 vs 1.3, P = 0.027]), but not in the kidneys (5.0 vs 10.4, P = 0.998). The highest area under the curve (AUC) was reported for prostate cancer (AUC, 0.978), and the lowest for penile cancer (AUC, 0.775). The detection rates based on the best suggested cutoff according to the SUVmax were 85.7% (6/7) for prostate and bladder and 83.3% (5/6) for penile cancer. Neither drug-related effects nor physiologic responses occurred, nor adverse reactions. Conclusions 64Cu(II)Cl2 is an effective and well-tolerated tracer in patients with UM. Our results show higher SUVmax in cancer patients than in healthy subjects. Our findings suggest that 64Cu(II)Cl2 PET/CT is useful in patients affected by prostate, bladder, and penis cancer.

68Ga-PSMA-11 PET/CT and 64CuCl2 PET/CT Help in Identifying Rare Metastatic Site of Penile Shaft in a Patient of Carcinoma Prostate

“…5-9 64 CuCl 2 PET/CT imaging is under evaluation for imaging various oncological conditions including carcinoma prostate. [10][11][12] In our case, there was agreement of both PET/CT studies in identifying the focal lesion in the shaft of the penis, detecting a rare soft tissue metastasis from carcinoma prostate and changing the staging of the patient.…”

Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent

“…Mascia M. et al evaluated the safety and efficacy of 64 CuCl 2 as a PET radiopharmaceutical to image other urological malignancies [25]. In this prospective study, a total of 23 patients were enrolled, including patients with renal cancer, bladder and penile cancer.…”

⁶⁴Cu²⁺Complexes of Tripodal Amine Ligands on In Vivo Tumor and Liver Uptake and Intracellular Cu Distribution in the Extrahepatic Bile Duct Carcinoma Cell Line TFK-1: A Basic Comparative Study

“…Therefore, targeting the Cu requirement of cancer cells is considered a promising avenue for the development of anticancer drugs. Several studies have been conducted to investigate the potential of 64 Cu 2+ ions as antitumor radiotherapeutic drugs [9][10][11][12][13]. 64 Cu is a useful radionuclide for theranostic purposes.…”